$237 Million is the total value of Affinity Asset Advisors, LLC's 54 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 66.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ESTA | Buy | ESTABLISHMENT LABS HLDGS INC | $19,574,000 | +66.4% | 359,956 | +106.3% | 8.25% | +338.6% |
| KURA | Buy | KURA ONCOLOGY INC | $17,015,000 | +14.5% | 928,256 | +0.4% | 7.17% | +201.7% |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $16,398,000 | +18.6% | 937,568 | +10.9% | 6.91% | +212.5% |
| NARI | Buy | INARI MED INC | $15,106,000 | -24.2% | 222,173 | +1.0% | 6.37% | +99.6% |
| ASND | Buy | ASCENDIS PHARMA A/Ssponsored adr | $11,628,000 | -17.4% | 125,087 | +4.2% | 4.90% | +117.6% |
| TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $10,901,000 | -5.2% | 11,000,000 | 0.0% | 4.60% | +149.9% | ||
| LLY | New | LILLY ELI & COcall | $9,727,000 | – | 30,000 | +100.0% | 4.10% | – |
| LNTH | Buy | LANTHEUS HLDGS INC | $9,244,000 | +45.3% | 140,000 | +21.7% | 3.90% | +282.8% |
| ESTA | New | ESTABLISHMENT LABS HLDGS INCput | $8,157,000 | – | 150,000 | +100.0% | 3.44% | – |
| Buy | NANOSTRING TECHNOLOGIES INCnote 2.625% 3/0 | $8,019,000 | +3.4% | 10,000,000 | +42.9% | 3.38% | +172.6% | |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $7,158,000 | -2.7% | 100,000 | +33.3% | 3.02% | +156.3% |
| HZNP | Buy | HORIZON THERAPEUTICS PUB L | $5,982,000 | +89.5% | 75,000 | +150.0% | 2.52% | +399.4% |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $5,693,000 | +498.6% | 45,000 | +500.0% | 2.40% | +1478.9% |
| KRTX | New | KARUNA THERAPEUTICS INCput | $5,693,000 | – | 45,000 | +100.0% | 2.40% | – |
| AZN | Sell | ASTRAZENECA PLCsponsored adr | $5,616,000 | -47.1% | 85,000 | -46.9% | 2.37% | +39.4% |
| MORF | Sell | MORPHIC HLDG INC | $4,681,000 | -75.0% | 215,723 | -53.7% | 1.97% | -34.0% |
| NVAX | New | NOVAVAX INCput | $4,629,000 | – | 90,000 | +100.0% | 1.95% | – |
| LNTH | Buy | LANTHEUS HLDGS INCput | $4,622,000 | +109.0% | 70,000 | +75.0% | 1.95% | +450.3% |
| BLU | Sell | BELLUS HEALTH INC NEW | $4,558,000 | +10.4% | 493,278 | -17.8% | 1.92% | +191.1% |
| RPTX | Sell | REPARE THERAPEUTICS INC | $4,494,000 | -32.7% | 321,200 | -31.5% | 1.89% | +77.3% |
| NVAX | New | NOVAVAX INCcall | $4,372,000 | – | 85,000 | +100.0% | 1.84% | – |
| CRSP | Buy | CRISPR THERAPEUTICS AGcall | $4,254,000 | +23.2% | 70,000 | +27.3% | 1.79% | +224.8% |
| BRIDGEBIO PHARMA INCnote 2.250% 2/0 | $4,237,000 | -9.5% | 10,000,000 | 0.0% | 1.79% | +138.5% | ||
| BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $4,154,000 | -5.2% | 7,500,000 | 0.0% | 1.75% | +149.8% | ||
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $4,048,000 | +2.3% | 1,372,244 | +7.9% | 1.71% | +169.5% |
| CLDX | New | CELLDEX THERAPEUTICS INC NEWcall | $3,909,000 | – | 145,000 | +100.0% | 1.65% | – |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $3,446,000 | -27.6% | 250,466 | -16.5% | 1.45% | +90.9% |
| Sell | ARYA SCIENCES ACQUISITN CORP | $3,426,000 | -49.8% | 352,500 | -49.8% | 1.44% | +32.2% | |
| LEGN | New | LEGEND BIOTECH CORPcall | $2,750,000 | – | 50,000 | +100.0% | 1.16% | – |
| MRNA | New | MODERNA INCcall | $2,143,000 | – | 15,000 | +100.0% | 0.90% | – |
| ZNTL | Sell | ZENTALIS PHARMACEUTICALS INC | $1,967,000 | -79.5% | 70,000 | -66.3% | 0.83% | -45.9% |
| Buy | CONTEXT THERAPEUTICS INC | $1,873,000 | +11.0% | 883,654 | +13.6% | 0.79% | +192.6% | |
| VINC | VINCERX PHARMA INC | $1,814,000 | -67.0% | 1,374,098 | 0.0% | 0.76% | -13.0% | |
| FATE | New | FATE THERAPEUTICS INCcall | $1,673,000 | – | 67,500 | +100.0% | 0.70% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INCcall | $1,656,000 | – | 150,000 | +100.0% | 0.70% | – |
| ACRS | ACLARIS THERAPEUTICS INC | $1,396,000 | -19.0% | 100,000 | 0.0% | 0.59% | +113.0% | |
| New | ARCELLX INC | $1,356,000 | – | 75,000 | +100.0% | 0.57% | – | |
| NAUT | Sell | NAUTILUS BIOTECHNOLOGY INC | $1,255,000 | -48.3% | 466,607 | -16.5% | 0.53% | +36.3% |
| COGT | New | COGENT BIOSCIENCES INC | $1,128,000 | – | 125,000 | +100.0% | 0.48% | – |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $1,078,000 | -74.7% | 40,000 | -68.0% | 0.45% | -33.3% |
| TERN | New | TERNS PHARMACEUTICALS INC | $995,000 | – | 401,268 | +100.0% | 0.42% | – |
| Buy | LIANBIOsponsored ads | $972,000 | -19.4% | 450,000 | +38.5% | 0.41% | +112.4% | |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $721,000 | – | 170,000 | +100.0% | 0.30% | – |
| Buy | CELULARITY INCput | $624,000 | -10.5% | 183,600 | +129.5% | 0.26% | +134.8% | |
| CYTK | New | CYTOKINETICS INC | $589,000 | – | 15,000 | +100.0% | 0.25% | – |
| Buy | SCIENCE 37 HOLDINGS INC | $562,000 | -52.5% | 279,775 | +26.4% | 0.24% | +25.4% | |
| RENOVACOR INC | $405,000 | -52.1% | 199,490 | 0.0% | 0.17% | +26.7% | ||
| ENOB | New | ENOCHIAN BIOSCIENCES INCput | $386,000 | – | 200,000 | +100.0% | 0.16% | – |
| IMTXW | IMMATICS N.V*w exp 07/01/202 | $382,000 | +16.5% | 187,204 | 0.0% | 0.16% | +209.6% | |
| CRIS | Sell | CURIS INC | $335,000 | -59.8% | 340,349 | -2.8% | 0.14% | +6.0% |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $239,000 | -74.2% | 20,660 | -58.7% | 0.10% | -31.8% |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $174,000 | – | 25,578 | +100.0% | 0.07% | – |
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $8,000 | -42.9% | 33,333 | 0.0% | 0.00% | +50.0% | |
| RENOVACOR INC*w exp 99/99/999 | $5,000 | -80.8% | 75,000 | 0.0% | 0.00% | -50.0% | ||
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -1,988 | -100.0% | -0.02% | – |
| Exit | HYPERFINE INC | $0 | – | -76,162 | -100.0% | -0.04% | – | |
| CALA | Exit | CALITHERA BIOSCIENCES INC | $0 | – | -1,000,000 | -100.0% | -0.06% | – |
| CNTA | Exit | CENTESSA PHARMACEUTICALS PLCsponsored ads | $0 | – | -65,282 | -100.0% | -0.09% | – |
| ATHX | Exit | ATHERSYS INC NEWput | $0 | – | -1,416,400 | -100.0% | -0.14% | – |
| CYCC | Exit | CYCLACEL PHARMACEUTICALS INC | $0 | – | -400,000 | -100.0% | -0.20% | – |
| BEAM | Exit | BEAM THERAPEUTICS INCcall | $0 | – | -30,000 | -100.0% | -0.28% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INCcall | $0 | – | -175,000 | -100.0% | -0.35% | – |
| RLAY | Exit | RELAY THERAPEUTICS INCcall | $0 | – | -75,000 | -100.0% | -0.36% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -70,000 | -100.0% | -0.39% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -80,000 | -100.0% | -0.39% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -70,000 | -100.0% | -0.39% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.41% | – |
| MSAC | Exit | MEDICUS SCIENCES ACQUISITION | $0 | – | -300,000 | -100.0% | -0.47% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQ CORP 2 | $0 | – | -300,000 | -100.0% | -0.48% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INCput | $0 | – | -215,900 | -100.0% | -0.82% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -171,592 | -100.0% | -0.95% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INCcall | $0 | – | -317,400 | -100.0% | -1.06% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -1.14% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INCput | $0 | – | -160,000 | -100.0% | -1.44% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -247,000 | -100.0% | -2.23% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -750,000 | -100.0% | -54.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-13 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.